153 related articles for article (PubMed ID: 20478851)
1. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.
Gong A; Chen X; Deng P; Zhong D
Drug Metab Dispos; 2010 Aug; 38(8):1328-40. PubMed ID: 20478851
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Yang Y; Liu K; Zhong D; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():25-30. PubMed ID: 22472641
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate.
Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
Sun M; Li S; Liu Z; Ma S; Liu X; Meng Q; Zheng Y; Chen C
Leuk Res; 2024 Jul; 142():107507. PubMed ID: 38692191
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of Flumatinib in Newly Diagnosed Chronic Myelogenous Leukemia.
Jiang L; Yang M
Pharmazie; 2023 Apr; 78(1):13-16. PubMed ID: 37138411
[TBL] [Abstract][Full Text] [Related]
6. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
Zhang L; Meng L; Liu B; Zhang Y; Zhu H; Cui J; Sun A; Hu Y; Jin J; Jiang H; Zhang X; Li Y; Liu L; Zhang W; Liu X; Gu J; Qiao J; Ouyang G; Liu X; Luo J; Jiang M; Xie X; Li J; Zhao C; Zhang M; Yang T; Wang J
Clin Cancer Res; 2021 Jan; 27(1):70-77. PubMed ID: 32928796
[TBL] [Abstract][Full Text] [Related]
7. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
8. Identification of imatinib mesylate degradation products obtained under stress conditions.
Szczepek WJ; Kosmacińska B; Bielejewska A; Łuniewski W; Skarzyński M; Rozmarynowska D
J Pharm Biomed Anal; 2007 Apr; 43(5):1682-91. PubMed ID: 17307328
[TBL] [Abstract][Full Text] [Related]
9. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Zhu Y; Li L; Zhang G; Wan H; Yang C; Diao X; Chen X; Zhang L; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():117-127. PubMed ID: 27541626
[TBL] [Abstract][Full Text] [Related]
10. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia.
Jiang B; Qi J; Sun M; Zheng W; Wei Y; Wang J; Zhang F
Front Oncol; 2023; 13():1101738. PubMed ID: 36814813
[TBL] [Abstract][Full Text] [Related]
12. Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Chen J; Guo S; Yu X; Lei J; Xu T; Zhu S; Chen L; Xu P; Zhou X; Yu L
Pharmazie; 2020 Sep; 75(9):424-429. PubMed ID: 32797767
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
14. Structure identification and elucidation of mosapride metabolites in human urine, feces and plasma by ultra performance liquid chromatography-tandem mass spectrometry method.
Sun X; Zhao L; Niu L; Qin F; Lu X; Xiong Z; Li F
Xenobiotica; 2014 Aug; 44(8):734-42. PubMed ID: 24417754
[TBL] [Abstract][Full Text] [Related]
15. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
16. Studies on the inhibitory effect of isavuconazole on flumatinib metabolism
Liu YN; Xu X; Nie J; Hu Y; Xu X; Xu RA; Du X
Front Pharmacol; 2023; 14():1168852. PubMed ID: 37214442
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
19. New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.
Müller MC
Clin Cancer Res; 2021 Jan; 27(1):3-4. PubMed ID: 33109738
[TBL] [Abstract][Full Text] [Related]
20. Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors.
Xu XL; Cao YJ; Zhang W; Rao GW
Curr Med Chem; 2022; 29(17):3050-3078. PubMed ID: 34636293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
